Posted by Michael Wonder on 03 Oct 2024
Calquence granted priority review in the US for patients with untreated mantle cell lymphoma
3 October 2024 - Submission to be reviewed under Project Orbis.
AstraZeneca’s supplemental new drug application for Calquence (acalabrutinib) has been accepted and granted priority review in the US for the treatment of adult patients with previously untreated mantle cell lymphoma.
